Genix Pharmaceuticals Corporation
GENX.V
TSX
| 01/31/2025 | 10/31/2024 | 07/31/2024 | 04/30/2024 | 01/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | 100.00 | 700.00 | 2.10K | 100.00 |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | 100.00 | 700.00 | 2.10K | 100.00 |
| Cost of Revenue | -- | 134.10K | 300.00 | 1.00K | 0.00 |
| Gross Profit | -- | -134.00K | 500.00 | 1.20K | 0.00 |
| SG&A Expenses | 21.30K | 44.80K | 30.00K | 29.30K | 29.70K |
| Depreciation & Amortization | 200.00 | 200.00 | 200.00 | 200.00 | 200.00 |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 21.50K | 179.10K | 30.50K | 30.50K | 30.00K |
| Operating Income | -21.50K | -179.00K | -29.80K | -28.30K | -29.90K |
| Income Before Tax | -75.50K | 112.80K | -60.00K | -63.30K | -43.70K |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -75.50K | 112.80K | -60.00K | -63.30K | -43.70K |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -75.50K | 112.80K | -60.00K | -63.30K | -43.70K |
| EBIT | -21.50K | -179.00K | -29.80K | -28.30K | -29.90K |
| EBITDA | -21.30K | -79.00K | 69.30K | 71.60K | -29.70K |
| EPS Basic | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Normalized Basic EPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS Diluted | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Normalized Diluted EPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Average Basic Shares Outstanding | 59.22M | 59.22M | 59.22M | 59.22M | 59.22M |
| Average Diluted Shares Outstanding | 59.22M | 59.22M | 59.22M | 59.22M | 59.22M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |